Your browser doesn't support javascript.
Nitric oxide pathway as a potential therapeutic target in COVID-19
Farmacia ; 68(6):966-969, 2020.
Article in English | Scopus | ID: covidwho-1005384
ABSTRACT
The Covid-19 viral infection is linked to a severe pulmonary reaction, leading to an acute lung injury in a large percentage of affected patients. Various inflammatory pathways regulated by SARS-CoV-2 are under-investigated. Some potential therapeutic options aimed to alleviate the inflammatory response of SARS-CoV-2 infection are involving different strategies for blocking the activation of its binding receptors on host cells and immunomodulation. Given that excessive lung inflammation is likely to cause death in Covid-19 patients, using nitric oxide (NO) pathway to mitigate this risk appears to be a reasonable approach to avoid serious lung injury. Such therapy could be paired with systemic immunomodulatory therapy to combat the multiple organ damage of Covid-19. Therefore, regulating the NO pathway has a potential therapeutic strategy to minimize the mortality of SARS-CoV-2 infection. © 2020, Romanian Society for Pharmaceutical Sciences. All rights reserved.

Full text: Available Collection: Databases of international organizations Database: Scopus Language: English Journal: Farmacia Year: 2020 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: Databases of international organizations Database: Scopus Language: English Journal: Farmacia Year: 2020 Document Type: Article